E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10008912 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess: • Antiviral activity, as determined by the proportion of subjects with eRVR in each cohort (prior partial responders and prior null responders), defined as undetectable HCV RNA at both Weeks 4 and 12; • Antiviral activity, as determined by the proportion of subjects with SVR24 in each cohort (prior partial responders and prior null responders), defined as undetectable HCV RNA at follow-up Week 24; • Safety, as measured by the frequency of SAEs and discontinuations due to AEs |
|
E.2.2 | Secondary objectives of the trial |
• To assess the proportion of subjects in each cohort (prior partial responders and prior null responders) with rapid virologic response (RVR), ie, undetectable HCV RNA at Week 4; • To assess the proportion of subjects in each cohort (prior partial responders and prior null responders with complete early virologic response (cEVR), ie, undetectable HCV RNA at Week 12; • To assess the proportion of subjects in each cohort (prior partial responders and prior null responders) with 12-week sustained virologic response (SVR12), ie, undetectable HCV RNA at follow-up Week 12; • To describe resistant variants associated with virologic failure. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Signed Written Informed Consent 2) Target Population a) Subjects chronically infected with HCV Genotype 1; b) Failure of prior pegIFNα/RBVtherapy as defined in Section 3.3.4; c) HCV RNA viral load of ≥ 100,000 IU/mL at screening; d) Results of liver biopsy obtained ≤ 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics, results of liver biopsy documenting cirrhosis can be from any time period prior to randomization (Compensated cirrhotics are capped at 10% of randomized population); e) Ultrasound (U/S), computed tomography (CT) scan, or magnetic resonance imaging (MRI) results 12 months prior to randomization that do not demonstrate evidence of HCC; f) Body Mass Index (BMI) of 18 to 35 kg/m�, inclusive. BMI = weight (kg)/[height (m)]� at screening. 3) Age and Reproductive Status a) Men or women, 18 to 70 years of age; b) Contraception requirements: Men and women of childbearing potential must be using 2 separate methods of contraception to avoid pregnancy throughout the study and for up to 24 weeks after the last dose of RBV (or time specified by the country specific RBV label, whichever is longer) in such a manner that the risk of pregnancy is minimized. See Section 3.3.3 for definition of WOCBP. One (1) form of contraception must be effective barrier method (eg, condom, diaphragm, cervical cap). Oral contraceptive pills (OCPs) may be used in this study as one of the two effective forms of contraception based on results of a drug interaction study with BMS-790052 and Ortho Tri-Cyclen. This contraception requirement applies in all cases of heterosexual intercourse in which the female partner is a WOCBP, except when the male partner is vasectomized for a minimum of 6 months; c) Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product. Female subjects must agree to the pregnancy testing requirements in this protocol; d) Women must not be breastfeeding; For further details, plese refer to the study protocol. |
|
E.4 | Principal exclusion criteria |
1) Target Disease Exceptions a) Infected with HCV other than genotype 1; b) Positive HBsAg, or HIV-1/HIV-2 antibody at screening. 2) Medical History and Concurrent Diseases a) Evidence of a medical condition associated with chronic liver disease other than HCV (such as but not limited to: hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, and toxin exposure); b) Evidence of decompensated cirrhosis based on radiologic criteria or biopsy results and clinical criteria; c) Current or known history of cancer within 5 years prior to enrollment (exceptions to this criteria are in situ carcinoma of the cervix or adequately controlled non-melanoma skin cancers); d) Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug; e) Any other medical, psychiatric and/or social reason including active substance abuse or alcohol abuse as defined by DSM-IV, Diagnostic Criteria for Drug and Alcohol Abuse (Appendix 1) which in the opinion of the investigator would make the candidate inappropriate for participation in this study; f) Inability to tolerate oral medication; g) Poor venous access. 3) Physical and Laboratory Test Findings a) Confirmed ALT ≥ 5 x ULN; b) Confirmed total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL); c) Confirmed INR ≥ 1.7; d) Confirmed albumin ≤ 3.5 g/dL (35 g/L); e) Confirmed platelets ≤ 90 billion cells/L; f) Confirmed ANC ≤ 1.5 billion cells/L; g) Confirmed hemoglobin ≤ 12 g/dL (120 g/L) for women and ≤ 13 g/dL (130 g/L) for men; h) Confirmed creatinine clearance (CrCl) (as estimated by Cockcroft and Gault) ≤ 50 mL/min; i) Patients with a screening QTcF > 450 msec (males) or > 470 msec (females), (three or more ECGs 5 minutes apart while subject is resting in a supine position will be used to establish baseline QTcF). 4) Medical History or Laboratory Findings that Exclude Subjects from Peg-Interferon Alfa-2a or Ribavirin Therapy The following exclusion criteria are based on guidelines or recommendations from the pegIFNα-2a and RBV package inserts: a) Severe psychiatric disease, especially untreated or unstable depression, that would prohibit used of pegIFNα-2a as judged by the investigator; b) History of hemoglobinopathies (ie, thalassemia major or sickle cell anemia), diagnoses associated with an increased baseline risk for anemia (eg, spherocytosis), hemolytic anemia, or disease in which anemia would be medically problematic; c) Thyroid-stimulating hormone (TSH) and/or T4 not within 0.8 to 1.2 times the normal limit, or not adequately controlled thyroid function as assessed by the investigator; d) History of chronic pulmonary disease associated with functional limitation; e) Unstable or clinically significant cardiovascular disease or hypertension that could be expected to progress, recur or change during study period to such an extent that it could bias the assessment of the clinical status of the patient; f) Pre-existing ophthalmologic disorders considered clinically significant on eye or retinal exam (all subjects with history of diabetes or hypertension must have a documented eye exam within 12 months prior to randomization);
For further details, see the study protocol. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Antiviral activity, as determined by the proportion of subjects with eRVR in each cohort (prior partial responders and prior null responders); • Antiviral activity, as determined by the proportion of subjects with SVR24 in each cohort; • Safety, as measured by the frequency of SAEs and discontinuations due to AEs. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 19 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of the last visit for the last subject to complete the study. The last visit is defined as the last post-treatment follow-up subject visit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |